Evidence map›Paper›PMID 33044586›Full record

ArticlePediatric cardiology2021

Establishing Baseline Metrics of Heart Failure Medication Use in Children: A Collaborative Effort from the ACTION Network.

Joseph Stidham, Brian Feingold, Christopher S Almond, Danielle S Burstein, Paige Krack, Jack F Price, Kurt R Schumacher, Joseph A Spinner, David N Rosenthal, Angela Lorts and 1 more

Abstract read
PubMed Publisher
In one paragraph

Article in Pediatric cardiology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.6field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 13 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 7 institutions in 1 country.

Joseph StidhamDepartment of Pediatrics, Vanderbilt University Medical Center, Nashville, TN, USA.
Brian FeingoldDivision of Pediatric Cardiology, University of Pittsburgh, Pittsburgh, PA, USA.
Christopher S AlmondDepartment of Pediatrics (Pediatric Cardiology), Stanford University, Palo Alto, CA, USA.
Danielle S BursteinDivision of Pediatric Cardiology, Children's Hospital of Philadelphia, Philadelphia, PA, USA.
Paige KrackDivision of Pediatric Cardiology, Cincinnati Children's Hospital, Cincinnati, OH, USA.
Jack F PriceDivision of Pediatric Cardiology, Texas Children's Hospital, Houston, TX, USA.
Kurt R SchumacherDivision of Pediatric Cardiology, University of Michigan, Ann Arbor, MI, USA.
Joseph A SpinnerDivision of Pediatric Cardiology, Texas Children's Hospital, Houston, TX, USA.
David N RosenthalDepartment of Pediatrics (Pediatric Cardiology), Stanford University, Palo Alto, CA, USA.
Angela LortsDivision of Pediatric Cardiology, Cincinnati Children's Hospital, Cincinnati, OH, USA.
Justin GodownDivision of Pediatric Cardiology, Vanderbilt University Medical Center, Nashville, TN, USA. Justin.Godown@vumc.org.ORCID http://orcid.org/0000-0002-7068-0625
Cincinnati Children's Hospital Medical Center · USStanford University · USTexas Children's Hospital · USVanderbilt University Medical Center · USChildren's Hospital of Philadelphia · USUniversity of Michigan · USUniversity of Pittsburgh · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Heart failure metrics specific to the pediatric population are required to successfully implement quality improvement initiatives in children with heart failure. Medication use at the time of discharge following admission for decompensated heart failure has been identified as a potential quality metric in this population. This study aimed to report medication use at discharge in the current era for children admitted with acute decompensated heart failure. All patients < 21 years of age with an index admission (1/1/2011-12/31/2019) for acute heart failure and a coexisting diagnosis of cardiomyopathy were identified from the Pediatric Health Information System. Medication use patterns were described and compared across age groups and centers. A total of 2288 patients were identified for inclusion. An angiotensin-converting enzyme inhibitor or an angiotensin receptor blocker (ACEi/ARB) was prescribed in 1479 (64.6%), beta blocker in 1132 (49.5%), and mineralocorticoid receptor antagonist (MRA) in 864 (37.8%) patients at discharge. The use of ACEi/ARB at discharge has decreased over time (64.6% vs. 69.6%, p = 0.001) and the use of beta blockers has increased (49.5% vs. 36.8%, p < 0.001) compared to a historical cohort (2001-2010). There is considerable variability in medication use across centers with an overall increase in beta blocker and decrease in ACEi/ARB use over time. Collaborative efforts are needed to standardize care and define quality metrics to identify best practices in the management of pediatric heart failure.

Indexed as

AdolescentAdrenergic beta-AntagonistsAngiotensin-Converting Enzyme InhibitorsAngiotensin Receptor AntagonistsBenchmarkingCardiomyopathiesCardiovascular AgentsChildChild, PreschoolFemaleHeart FailureHospitalizationHumansMaleMineralocorticoid Receptor AntagonistsPatient DischargeAdrenergic beta-AntagonistsAngiotensin-Converting Enzyme InhibitorsAngiotensin Receptor AntagonistsCardiovascular AgentsMineralocorticoid Receptor AntagonistsHeart failureMedicationPediatricQuality improvement

Identifiers

PMID33044586
OpenAlexW3091774364

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.